1. Home
  2. TAOP vs ENTO Comparison

TAOP vs ENTO Comparison

Compare TAOP & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TAOP
  • ENTO
  • Stock Information
  • Founded
  • TAOP 1993
  • ENTO 2014
  • Country
  • TAOP China
  • ENTO United States
  • Employees
  • TAOP N/A
  • ENTO N/A
  • Industry
  • TAOP Computer Software: Prepackaged Software
  • ENTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • TAOP Technology
  • ENTO Health Care
  • Exchange
  • TAOP Nasdaq
  • ENTO Nasdaq
  • Market Cap
  • TAOP 2.7M
  • ENTO 1.9M
  • IPO Year
  • TAOP N/A
  • ENTO 2016
  • Fundamental
  • Price
  • TAOP $7.37
  • ENTO $0.43
  • Analyst Decision
  • TAOP
  • ENTO
  • Analyst Count
  • TAOP 0
  • ENTO 0
  • Target Price
  • TAOP N/A
  • ENTO N/A
  • AVG Volume (30 Days)
  • TAOP 1.6M
  • ENTO 3.1M
  • Earning Date
  • TAOP 06-10-2025
  • ENTO 05-15-2025
  • Dividend Yield
  • TAOP N/A
  • ENTO N/A
  • EPS Growth
  • TAOP N/A
  • ENTO N/A
  • EPS
  • TAOP N/A
  • ENTO N/A
  • Revenue
  • TAOP $36,672,512.00
  • ENTO N/A
  • Revenue This Year
  • TAOP N/A
  • ENTO N/A
  • Revenue Next Year
  • TAOP N/A
  • ENTO N/A
  • P/E Ratio
  • TAOP N/A
  • ENTO N/A
  • Revenue Growth
  • TAOP N/A
  • ENTO N/A
  • 52 Week Low
  • TAOP $4.26
  • ENTO $0.19
  • 52 Week High
  • TAOP $29.40
  • ENTO $2.86
  • Technical
  • Relative Strength Index (RSI)
  • TAOP 49.34
  • ENTO 55.80
  • Support Level
  • TAOP $7.41
  • ENTO $0.37
  • Resistance Level
  • TAOP $8.78
  • ENTO $0.68
  • Average True Range (ATR)
  • TAOP 2.85
  • ENTO 0.08
  • MACD
  • TAOP -0.02
  • ENTO 0.00
  • Stochastic Oscillator
  • TAOP 11.93
  • ENTO 25.15

About TAOP Taoping Inc.

Taoping Inc is a provider of cloud-app technologies for smart city IoT platforms, digital advertising delivery, and other internet-based information distribution systems in China. Its operating segment includes Cloud-based Technology (CBT), Blockchain Technology (BT), and Traditional Information Technology (TIT). It generates maximum revenue from the CBT segment. CBT segment includes cloud-based products and services offered to customers in the private sector including new media, healthcare, education, and residential community management.

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: